CMPX vs COP
Compass Therapeutics Inc. (CMPX) versus ConocoPhillips (COP) — a side-by-side from cached financials, not a winner call.
Compass Therapeutics Inc. (CMPX) is a biotechnology company listed on US.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
CMPX does not have a complete income-statement cache yet.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
CMPX currently screens at market cap $367.4M. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Not investment advice. Open the CMPX and COP stock pages for the full models.
Not investment advice.